Physician profile
Umer Hayyat
NPI 1851812499
$832.62
in general payments reported to CMS, 2019-2025
12 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.69 · 2020: $28.16 · 2021: $84.30 · 2022: $182 · 2023: $79.06 · 2024: $142 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $149.14 | 2025 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $141.88 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $141.77 | 2024 | Lifevest |
| Biosense Webster, INC. | $138.46 | 2025 | Carto 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $106.67 | 2022 | |
| Bioxcel Therapeutics, INC. | $42.22 | 2023 | Igalmi |
| Astellas Pharma US INC | $28.16 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.36 | 2022 | |
| Pfizer INC. | $17.68 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.59 | 2022 | |
| Abbvie INC. | $16.55 | 2019 | |
| Novo Nordisk INC | $13.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umer Hayyat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.